nominally significant difference was observed in the G1-4 haplotype (C-G-T in Table 2), which reflects the potential for a small role of GABRG1 in AD risk in AAs, but the difference in GABRA2 haplotype frequencies was much more statistically significant (Table 3). The most significantly-associated risk haplotype (p=0.00019, OR=2.83, 95%CI=1.57-5.41) was A2-4 (G-T-A), which was estimated to be present on 65 chromosomes (8.6%) in AD subjects compared to only 16 chromosomes (3.2%) in the control group. Another haplotype that was less significant in the AD group than the control group, A2-5 (A-G-G with p=0.00042), was completely absent in the control group (such that the OR could not be calculated).
